CuraGen Releases Single-Dose Phase I Data on Velafermin

CuraGen has reported the final Phase I results for a single-dose of velafermin (CG53135) for the prevention of oral mucositis (OM) in patients receiving high-dose chemotherapy followed by autologous hematopoietic stem cell transplantation.

The final results from this Phase I study suggest velafermin (CG53135) is well-tolerated following intravenous administration with data supporting the company's ongoing Phase II trial and strategy of investigating a single-dose of velafermin (CG53135) for the prevention of OM.